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This study investigated the potential of stevioside to prevent oxidative DNA
damage in the liver and kidney of type 2 diabetes mellitus (T2DM) using high
fat-low streptozocin rat model. Rats were treated daily with 12.5, 25 and 50 mg/
kg stevioside orally for 21 days. Levels of biomarkers of T2DM, lipid proﬁle
and oxidative stress were assayed spectrophotometrically. The DNA ladder assay
method was used to assess DNA fragmentation in the liver and kidney while
computational analysis was used to predict the mechanisms of antidiabetic
properties of stevioside. Stevioside signiﬁcantly (p < 0.05) decreased the levels
of plasma glucose, insulin, dipeptidyl peptidase IV and activities of kidney
angiotensin converting enzyme. Stevioside signiﬁcantly reduced oxidative stress
by decreasing the levels of lipid peroxidation and nitric oxide in the liver and
kidney; thereby, reducing the extent of DNA fragmentation in the liver and
kidney of the diabetic rats. The in silico analysis showed that the ability of
stevioside to exert these eﬀects is linked to its inhibition of beta-adrenergic
receptor kinase and G-protein-coupled receptor kinase. The results of this study.e00640
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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the use of stevioside in the management of T2DM.
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1. Introduction
Type 2 diabetes mellitus (T2DM) is a life-threatening metabolic disease that is reach-
ing epidemic proportions [1]. T2DM is responsible for about 5 million deaths annu-
ally due largely to major complications like atherosclerotic coronary heart disease,
cardiomyopathy, stroke and nephropathy. Globally, undiagnosed diabetes continues
to predispose about 200 million people to the development of several long-term mi-
cro and macrovascular complications of unmanaged chronic hyperglycemia [1].
These complications are consequences of glucotoxicity-induced oxidative stress
with concomitant damage to biomolecules [2]. In particular, the damage to DNA
has been linked to enhanced cancer risk, and patients with diabetes mellitus have
been shown to have an increased cancer incidence [3]. Hence, oxidative damage
to DNA does not often lead to severe vascular complications with a phenotypic
outcome synonymous with diabetes [3].
The rise in diabetes prevalence mirrors the rise in its main risk factors-overweight
and obesity, as well as increase in sugar consumption [4, 5]. Hence, the urgent
need to control this trend requires a scrupulous control of diet and sugar intake.
However, the cognitive desire of human for sugar or sweet diet seems insatiable
[6]. Therefore, it is imperative to investigate the role of non-caloric sweeteners in
the management of diabetes.
Stevioside (PubChem CID:442089) is one of natural non-caloric sweeteners reﬁned
from the leaves of Stevia rebaudiana Bertoni. It is recognized to be 250 times
sweeter than sucrose (4 g/L) and is used as non-caloric alternative to table sugar
[7]. The Joint FAO/WHO Expert Committee on Food Additives recommended ste-
vioside’s admissible daily intake to be less than or equal to 4 mg/kg body weight,
based on no-observed-adverse-eﬀect level of 970 mg/kg body weight per day (383
mg/kg bw per day expressed as steviol equivalent) [8]. Stevioside is a glycoside
and it is hydrolyzed to steviol (the aglycone) in the caecum by intestinal micro-
ﬂora under anaerobic conditions [9]. The plasma concentration of steviol has
been reported to reach the peak after 15 min of oral administration, demonstrating
rapid absorption [9]. Long-term oral intake of stevioside has been shown to be
highly tolerated in human with no apparent side eﬀect at dietary dosage [10]. Be-
sides sweetness, many studies have reported the therapeutic beneﬁts of glycosides
derived from Stevia rebaudiana, which include anti-oxidant, anti-hyperglycemic,
anti-hypertensive, anti-inﬂammatory, anti-tumor, anti-diarrheal, diuretic, andon.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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increased use and commercialization of its production [13].
Although, previous studies have reported the hypoglycemic property of stevioside
[14], more detailed studies are still needed to understand the mechanism by which
it improves T2DM and prevents its associated complications. This present study
therefore seeks to investigate the eﬀects of stevioside on oxidative damage in a
high fat fed/streptozotocin-induced T2DM rat model. This model is associated
with initial insulin resistance and/or glucose intolerance following streptozocin-
induced destruction of functional b-cell mass; hence, mimicking the pathology of
human T2DM [15, 16]. Using this model, we therefore, hypothesize that the antigly-
cemic and antioxidant properties of stevioside will be beneﬁcial in protecting DNA
from oxidative damage in the diabetic rats.2. Materials and methods
2.1. Chemicals
Streptozotocin was a product of Sigma-Aldrich (St. Loius, MO, USA) while stevio-
side (95%) was a product of Anhui Minmetals Development Co., Hefei, Anhui,
China. DNA extraction spin column kit was a product of Aidlab Biotechnologies
Co. Ltd (Beijing, China) while kits for Enzyme-linked immunosorbent assays
(ELISA) were products of Hangzhou Eastbiopharm Co., Hangzhou, China. All other
chemicals were products of Sigma-Aldrich (St. Loius, MO, USA).2.2. Animals
Thirty male inbred albino rats weighing between 150 and 200 g were used for this
study. The rats were housed under normal temperature (22  2 C) with 12-h light
and dark cycle. The animals were allowed to acclimatize for three weeks before
commencement of the experiment. The experiment was approved by the Covenant
University Ethical Committee (CU/BIOSCRECU/BIO/2015/004) and carried out
according to the guidelines of the committee.2.3. Experimental design
The rats were randomly divided into ﬁve groups of six rats each. Four of the groups
were maintained on a high fat diet (HFD), which contained 50% fat (5% from vege-
table oil and 45% from tallow) (Table 1), throughout the period of the experiment (9
weeks) while the last group was maintained on normal pellet diet (5% fat from vege-
table oil) and served as the normal control. After 4 weeks, the HFD fed groups were
given a low dose (35 mg/kg body weight) of streptozocin intraperitoneally while the
normal control group was administered the vehicle (0.1 mL/kg body weight of 0.1 Mon.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 1. Composition of diet.
Component Level (g/100 g) in diet
Normal diet High fat diet
Fish meal 25 25
Sucrose 10 10
Corn starch 49.5 4.5
Vegetable oil 5 5
Salt/mineral mixa 5.5 5.5
Cellulose 5 5
Tallow 0 45
a Salt/mineral mix contains the following (in g/100 g): calcium phosphate, 49.50; sodium powder, 11.80;
potassium sulfate, 5.20; sodium chloride, 7.40; magnesium oxide, 2.40; potassium citrate, 22.40; ferric
citrate, 0.60; manganous carbonate, 0.35; cupric carbonate, 0.03; zinc carbonate, 0.16; chromium potas-
sium sulfate, 0.055; potassium iodate, 0.001; sodium selenate, 0.001; choline chloride, 0.50; thiamine
HCl, 0.06; riboﬂavin, 0.06; niacin, 0.30; calcium pantothenate, 0.16; biotin, 0.01; vitamin B12, 0.10;
vitamin D3, 0.025; vitamin E acetate, 1.00; pyridoxine, 0.07; folic acid, 0.02; vitamin A acetate, 0.08.
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administered at week 6 of the experiment, after which fasting blood glucose was
checked and stevioside was then administered orally for 21 days. The rats were
grouped as shown below;
Group 1: Normal Control: Rats fed normal diet (n ¼ 6)
Group 2: Diabetic Control: Rats fed HFD (n ¼ 6)
Group 3: Diabetic rats treated with 12.5 mg/kg stevioside: Rats fed HFD (n ¼ 6)
Group 4: Diabetic rats treated with 25 mg/kg stevioside: Rats fed HFD (n ¼ 6)
Group 5: Diabetic rats treated with 50 mg/kg stevioside: Rats fed HFD (n ¼ 6)
Twenty-four hours after the last dose of stevioside, blood was collected from the an-
imals by cardiac puncture under light ether anesthesia after an overnight fast; liver
and kidney were also excised for analysis. Tissue homogenates were prepared as
described by Rotimi et al. [18, 19].2.4. Biochemical analysis
2.4.1. Plasma chemistry
Glucose, bicarbonate, hydroxyl butyrate dehydrogenase, alkaline phosphatase
(ALP), urea, creatinine kinase (CK), a-amylase, gamma-glutamyl transferase
(GGT) and lactate dehydrogenase (LDH) were determined spectrophotometrically
in the plasma using commercially available kits according to manufacturer’s instruc-
tions (Jinan Biobase Biotech Co.,Ltd, Jinan, China) while insulin and dipeptidylon.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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(ELISA) kits (Hangzhou Eastbiopharm Co., Ltd. Hangzhou, China).2.4.2. Determination of angiotensin converting enzyme (ACE)
activity
ACE was determined in the kidney spectrophotometrically, using the conversion of
N-HippuryleHis-Leu hydrate, hydrochloric acid (HHL) to hippuric acid according
to the method of Cushman and Cheung [20]. Brieﬂy, assay solution consisted of 5
mM HHL in 100 mM sodium borate buﬀer (pH 8.3). The reaction was initiated by
addition of 10 mL of kidney homogenate and incubated at 37 C for 30 min. There-
after, the reaction was terminated by the addition of 1 M HCl and the amount of hip-
puric acid released was monitored at 228 nm.2.4.3. Plasma lipid proﬁles
Plasma cholesterol and triacylglycerols were determined spectrophotometrically us-
ing commercially available kits according to manufacturer’s instructions (Jinan Bio-
base Biotech Co.,Ltd, Jinan, China). High Density Lipoprotein (HDL) and HDL3
were obtained from the plasma using the Dextran sulfateeMgCl2 precipitation
method as described by Rifai et al. [21]. The supernatant obtained after centrifuga-
tion contained the HDL and HDL3 while the precipitate contained VLDL and
VLDL3 respectively. Free fatty acid was determined spectrophotometrically as
described by Rotimi et al. [18, 19].2.4.4. Oxidant/antioxidant status assays
Lipid Peroxidation was determined by measuring the concentration of thiobarbituric
acid reactive substances (TBARS) according to the method of Buege and Aust [22].
Nitric oxide (NO) concentration was determined by the Griess reaction using a
method described by Yucel et al [17]. Glutathione (GSH) concentration in the tissues
were determined according to the method described by Ellman [23] while
glutathione-S-transferase (GST) activity was determined by measuring the formation
of 1-chloro-2,4-dinitrobenzene and GSH conjugate at 340 nm according to the
method described by Habig et al. [24]. Glutathione peroxidase (GPx) activity was
determined according to the method of Rotruck et al. [25] while glutathione reduc-
tase (GR) activity was assayed as described by Mavis and Stellwagen [26]. Super-
oxide dismutase (SOD) activity was determined according to the pyrogallol
autoxidation method of Marklund and Marklund [27] while peroxidase (PER) activ-
ity was determined according to the method of Fergusson and Chance [28]. The ac-
tivities of the enzymes in each organ were expressed per mg protein as previously
described [29], following the determination of protein concentration as described
by Lowry et al. [30].on.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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fragmentation
Genomic DNA was extracted from the liver and kidney using the spin column tech-
nique according to manufacturer’s instructions (Aidlab Biotechnologies Co. Ltd.,
China). Quality and concentration of DNA was determined spectrophotometrically
at 260 nm using Nanodrop spectrophotometer (Thermo Scientiﬁc, Fisher Scientiﬁc
Company, Suwanee, GA, USA). After normalization of the DNA concentration, the
DNA ladder assay method was used as described by Suman et al. [31], using 0.8%
agarose. The agarose gel was stained with ethidium bromide and visualized using the
UVP GelDoc-It imaging system. The intensity of the DNA on agarose gel was
analyzed using Image J software.2.4.6. Computational analysis
The biological activities spectra that relates to T2DM, of stevioside was predicted
using a prediction of activity spectra for substances (PASS)-based approach as
described by Filimonov et al. [32]. PASS is an online algorithm that estimates pre-
dicted activity spectrum of a compound as probable activity (Pa) and probable inac-
tivity (Pi). It utilizes a structure-activity relationship analysis to predict activities and
it has been trained with a set containing more than 250,000 of biologically active
compounds. The values of Pa and Pi vary between 0.000 and 1.000. Only activitiesFig. 1. (aed): Eﬀects of stevioside on biomarkers of diabetes in the experimental rats. (a) level of plasma
glucose, (b) level of plasma bicarbonate, (c) activity of plasma hydroxyl butylrate dehygrogenase, and (d)
level of plasma free fatty acids. Bars represent mean  SEM (n ¼ 6). Bars with diﬀerent statistical
markers are signiﬁcantly diﬀerent at p < 0.05.
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probability of experimental pharmacological action is high, and if 0.5 < Pa < 0.7,
the probability of experimental pharmacological action is less.2.4.7. Statistical analysis
Data were expressed as mean  SEM of six replicates in each group. Analysis of
variance (ANOVA) was carried out to test for the level of homogeneity at p <
0.05 among the groups. Duncan’s multiple range test was used to separate the het-
erogeneous groups.3. Results
3.1. Eﬀects of stevioside administration on biomarkers T2DM
The levels of glucose, bicarbonate, free fatty acids (FFA) and activity of hydroxybu-
tyrate dehydrogenase were assessed in the plasma of the rats [Fig. 1(aed)]. Further-
more, the levels of plasma DPP IV and plasma insulin, as well as the activity of
kidney ACE were assayed [Fig. 2(aec)] as biomarkers of T2DM. T2DM,Fig. 2. (aec): Eﬀects of stevioside on speciﬁc biomarkers of T2DM in the experimental rats. (a) level of
plasma DPP IV, (b) level of plasma insulin, and (c) activity of kidney ACE. Bars represent mean  SEM
(n ¼ 6). Bars with diﬀerent statistical markers are signiﬁcantly diﬀerent at p < 0.05.
on.2018.e00640
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IV and bicarbonate while all the doses of stevioside resulted in a signiﬁcant
(p< 0.05) decrease when compared with the diabetic control. Treatment with stevio-
side signiﬁcantly (p< 0.05) decreased the concentrations of plasma DPP IV to levels
signiﬁcantly (p< 0.05) lower than the normal control. 50 mg/kg dose and, 25 and 50
mg/kg doses had the lowest concentrations of DPP IV and insulin respectively.
T2DM also signiﬁcantly (p < 0.05) increased the activity of ACE in the kidney
and concentration of plasma FFA. Stevioside treatment resulted in a dose-
dependent signiﬁcant (p < 0.05) decreases in both biomarkers, with 25 mg/kg treat-
ment giving the optimum reductions.
The activities of plasma ALP, CK, amylase, GGT and LDH, as well as the level of
plasma urea are depicted in Fig. 3(aef). T2DM signiﬁcantly (p< 0.05) increased the
activities of ALP, amylase and GGT, as well as the level of urea. The activities ofFig. 3. (aef): Eﬀects of stevioside on biomarkers of organ function the experimental rats. (a) activity of
plasma alkaline phosphatase, (b) level of plasma urea, (c) activity of plasma creatinine kinase, (d) activity
of plasma amylase, (e) activity of plasma gamma-glutamyl transferase, and (f) activity of plasma lactate
dehydrogenase. Bars represent mean  SEM (n ¼ 6). Bars with diﬀerent statistical markers are signif-
icantly diﬀerent at p < 0.05.
on.2018.e00640
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of amylase activity was dose-dependent with 50 mg/kg having the highest reduction.
Although, level of plasma urea was signiﬁcantly (p < 0.05) reduced by stevioside
treatment, this reduction was signiﬁcantly (p < 0.05) reversed at 50 mg/kg. Howev-
er, this dosage signiﬁcantly (p < 0.05) reduced the activity of GGT.3.2. Stevioside administration reduced dyslipidemia
Fig. 4(aef) shows the levels of cholesterol and triacylglycerols in the rats. T2DM
signiﬁcantly (p < 0.05) increased the concentrations of plasma cholesterol and tria-
cylglycerols while it decreased the concentration of HDL1 triacylglycerols. There
was no signiﬁcant diﬀerence in the concentrations of HDL1 cholesterol, HDL3
cholesterol and HDL3 triacylglycerols compared with normal control. All the doses
of stevioside signiﬁcantly (p< 0.05) decreased plasma cholesterol and triacylglycer-
ols compared with diabetic control, with the highest dose having the most signiﬁcant
(p < 0.05) decrease. All the doses of stevioside signiﬁcantly reversed theFig. 4. (aef): Eﬀects of steviosdie on plasma lipid proﬁle in the experimental rats. (a) level of plasma
total cholesterol, (b) level of plasma total triacylglycerols, (c) level of HDL1 cholesterol, (d) level of
HDL1 triacylglycerols, (e) level of HDL3 cholesterol, and (f) level of HDL3 triacylglycerols. Bars repre-
sent mean  SEM (n ¼ 6). Bars with diﬀerent statistical markers are signiﬁcantly diﬀerent at p < 0.05.
on.2018.e00640
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normal control while the 25 and 50 mg/kg doses signiﬁcantly (p < 0.05) increased
HDL3 triacylglycerols when compared with normal and diabetic controls.3.3. Stevioside reversed oxidative stress and damage
The activities of hepatic SOD, GST, GSH, GPx, PER, and GR were signiﬁcantly
decreased while the concentrations of TBARS and NO were signiﬁcantly
(p < 0.05) increased by T2DM (Fig. 5(aeh)). All the doses of steviosideFig. 5. (aeh): Eﬀects of stevioside on biomarkers of oxidative stress in the liver of the experimental rats.
(a) level of thiobarbituric reactive substances, (b) level of nitric oxide, (c) activity of superoxide dismut-
ase, (d) activity of peroxidase, (e) level of reduced glutathione, (f) activity of glutathione peroxidase, (g)
activity of glutathione-S-transferase, and (h) activity of glutathione reductase. Bars represent mean 
SEM (n ¼ 6). Bars with diﬀerent statistical markers are signiﬁcantly diﬀerent at p < 0.05.
on.2018.e00640
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diabetic control while it decreased SOD with the 50 mg/kg having the most decrease.
Only 25 and 50 mg/kg dose increased the levels of GSH, GPx and PER. All the
doses of stevioside signiﬁcantly decreased the concentrations of TBARS and NO
when compared with diabetic control. The decrease resulting from 25 and 50 mg/
kg doses were not signiﬁcantly (p > 0.05) diﬀerent from each other.
T2DM signiﬁcantly (p < 0.05) decreased the levels of SOD, GST, GSH, GPx, PER
and GR while it increased that of TBARS and NO in the kidney (Fig. 6(aeh)).Fig. 6. (aeh): Eﬀects of stevioside on biomarkers of oxidative stress in the kidney of the experimental
rats. (a) level of thiobarbituric reactive substances, (b) level of nitric oxide, (c) activity of superoxide dis-
mutase, (d) activity of peroxidase, (e) level of reduced glutathione, (f) activity of glutathione peroxidase,
(g) activity of glutathione-S-transferase, and (h) activity of glutathione reductase. Bars represent mean 
SEM (n ¼ 6). Bars with diﬀerent statistical markers are signiﬁcantly diﬀerent at p < 0.05.
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only the 25 and 50 mg/kg doses of stevioside signiﬁcantly (p < 0.05) increased the
concentrations of GSH when compared with the diabetic control. All doses of stevio-
side were unable to increase the diabetic-induced decrease in the activities of GPx,
PER and GR. This trend was also observed in SOD, however, the 50 mg/kg dose led
to a further decrease in SOD activity when compared with the control. All doses of
stevioside signiﬁcantly (p < 0.05) decreased the diabetic-induced increase in the
concentrations of TBARS and NO. While 25 and 50 mg/kg doses resulted in de-
creases in TBARS and NO signiﬁcantly (p < 0.05) diﬀerent from the 12.5 mg/kg
group, these doses reduced only NO to levels not signiﬁcantly (p < 0.05) diﬀerent
from the control group.Fig. 7. (aed) Eﬀect of stevioside on the intra-nucleosomal DNA fragmentation. (a) the pattern of DNA
ladder of the liver, (b) the pattern of DNA ladder of the kidney, (c) agarose gel image of liver DNA frag-
mentation and (d) agarose gel image of kidney DNA fragmentation. Group 1: Normal Control, Group 2:
Diabetic Control, Group 3: Diabetic rats treated with 12.5 mg/kg stevioside, Group 4: Diabetic rats
treated with 25 mg/kg stevioside and Group 5: Diabetic rats treated with 50 mg/kg stevioside.
on.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Table 2. PASS-predicted antidiabetic activities of stevioside.
Pa Pi Activity
1 0.799 0.013 Beta-adrenergic receptor kinase inhibitor
2 0.799 0.013 G-protein-coupled receptor kinase inhibitor
3 0.786 0.005 Antidiabetic
4 0.764 0.001 Alpha glucosidase inhibitor
5 0.721 0.005 Antidiabetic (type 2)
6 0.718 0.007 Cholesterol antagonist
7 0.637 0.009 Beta glucuronidase inhibitor
8 0.630 0.021 Glucan endo-1.3-beta-D-glucosidase
inhibitor
9 0.575 0.004 Nitric oxide antagonist
10 0.498 0.007 Antioxidant
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increased in the diabetic control group compared with other groups. All doses of ste-
vioside signiﬁcantly (p < 0.05) decreased the fragmentation in the liver and kidney
when compared with the diabetic control (Fig. 7(aeb)). The 12.5 and 25 mg/kg
doses signiﬁcantly (p < 0.05) decreased the kidney DNA fragmentation to levels
not signiﬁcantly (p > 0.05) diﬀerent from the normal control while the 50 mg/kg
dose was signiﬁcantly (p < 0.05) lower than the normal control.3.4. In silico predictions of biological activities of stevioside
Table 2 showed the PASS-based anti-T2DM activities of stevioside. Apart from its
antidiabetic property, other biological activities include very high inhibition of beta-
adrenergic receptor kinase, G-protein-coupled receptor kinase, alpha glucosidase in-
hibitor, beta glucuronidase inhibitor and glucan endo-1.3-beta-D-glucosidase inhib-
itor. PASS also indicated the antioxidant as well as the cholesterol and nitric oxide
antagonistic properties of stevioside.4. Discussion
Stevioside improved oxidative stress and damage associated with T2DM and also
reduced the associated increase in biomarkers of T2DM. Although the admissible
daily intake for steviol glycosides is 0e4 mg/kg body weight (expressed as steviol),
the concentration used in this study were of pharmacological signiﬁcance in rats and
below the reported toxicity level [33, 34].
The results of this study showed that the rise in blood glucose was associated with a
concomitant increase in biomarkers of T2DM, which include DPP IV, bicarbonate,
hydroxybutyrate dehydrogenase dehydrogenase and FFA [35, 36]. This is consistenton.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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that stevioside administration resulted in mild but signiﬁcant reduction in plasma
glucose and other biomarkers of T2DMmeasured. Of particular interest is the reduc-
tion in the level of DPP IV e a biomarker of T2DM that has been reported to be
beneﬁcial in the management of T2DM by previous authors [38, 39]. This further
validates the in silico results indicating the potential of stevioside as an anti-
T2DM agent. This could be due to the beta glucuronidase and glucan endo-1.3-
beta-D-glucosidase inhibitory properties of stevioside. The inhibition of these en-
zymes regulate carbohydrate digestion and release of glucose in the gastrointestinal
tract and has been recognized as potential mechanism of hypoglycemic agents [40].
Previous studies have reported the hypoglycemic property of stevioside but none has
indicated the inhibition of these enzymes as part of the mechanisms.
A number of hypoglycemic agents that inhibit the release of glucose in the GIT often
results in the buildup of bicarbonate. In contrast, the hypoglycemic property of ste-
vioside was accompanied with decrease in bicarbonate level together with insulin.
This is an indication that the glucose uptake by the cells was enhanced thereby
reducing lipolysis. In T2DM, cells rely on lipolysis as an alternative source of energy
by upregulating b-oxidation of FFA to form ketone bodies [36]. This condition,
known as diabetic ketoacidosis, is a known life-threatening acute complication of
diabetes. Diabetic acidosis is characterized by the build of bicarbonate in the blood
and increase in the activity of b-hydroxybutyrate dehydrogenase. b-hydroxybutyrate
dehydrogenase converts b-hydroxybutyrate to acetoacetate. The acetoacetate is
further converted to acetoacetyl-CoA, which is then split into two acetyl-CoA that
are utilized in the TCA cycle to generate ATP in peripheral tissues [41].
Increase in b-hydroxybutyrate dehydrogenase activity could serve as a surrogate
biomarker for both insulin resistance and impaired glucose regulation [42]. This
further support the increase in insulin level along with glucose and b-hydroxybuty-
rate dehydrogenase activity observed in the diabetic untreated animals. The shift in
energy metabolism from glucose to fatty acid results in alterations in several signal
transduction pathways, which is now known to involve the G protein-coupled recep-
tor kinase 2 (GRK2)-integrated signal transduction pathways [43]. Emerging evi-
dences now suggest that increase in GRK2 activity contribute to the development
of T2DM, and inhibiting GRK2 could reverse an established insulin-resistance
[44]. It of interest that stevioside has GRK2 inhibitory property, as shown by
PASS analysis in silico results. Hence, the ability of stevioside to reverse insulin
resistance and enhance uptake of glucose could be due to its ability to inhibit GRK2.
The hypoglycemic eﬀect of stevioside was also associated with decrease in plasma
amylase activity, as well as decrease in some biomarkers of organ function. Howev-
er, it is of concern that stevioside at 50 mg/kg resulted in increase in plasma urea.
This shows that at this concentration of stevioside could be toxic to the kidney.on.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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side at high concentration could be nephrotoxic [44, 45]. Also, we had earlier ex-
pressed the need to consider nephrotoxic implication of hypoglycemic regime [46].
A major macrovascular complication associated with T2DM is hypertension, and
this comorbidity is responsible for high mortality due to this disease [1, 46]. The
pathogenesis of hypertension involves elevation of renal angiotensin converting
enzyme [47] and previous studies have identiﬁed its elevation in T2DM [48]. Hence,
inhibiting this enzyme is a major target of antihypertensive therapies [49]. The ﬁnd-
ings of this study showed that stevioside reduced the elevation of renal angiotensin
converting enzyme in the diabetic rats. This could therefore, explain the antihyper-
tensive property of stevioside earlier reported [50, 51], and validated in human hy-
pertension [52].
The shift in cellular energy source from glucose to fatty acids and the associated in-
sulinemia result in dyslipidemia and cardiovascular complications in T2DM [53].
The in silico analysis showed that stevioside possesses a strong cholesterol antago-
nistic property, and this could account for the reduction in cholesterol level.
Although previous studies have reported the cholesterol lowering properties of ste-
vioside, none has associated it to its cholesterol antagonistic property. Another
possible mechanism of improving dyslipidemia is by inhibiting G-protein-coupled
receptor kinase. Altered lipid metabolism following high-fat diet-induced dyslipide-
mia has been shown to upregulate kinase and it is a therapeutic target [42, 54].
A major biochemical consequence of dyslipidemia is the FFAs activation of NADPH
oxidase, which induces reactive oxygen species (ROS) production and ROS induced
oxidative stress [55]. The role of ROS in the pathogenesis of diabetes, and its compli-
cations, has been reported by many researchers [40, 46, 55]. In this study, oxidative
stress in liver and kidney was characterized with increased lipid peroxidation and
NO with a decrease in the level of GSH as well as the activities of PER, SOD, GST
and GPx. The depletion of these antioxidants has been reputed to expose major macro-
molecules to the peroxidative damaging eﬀects of ROS [55]. This leads to lipid perox-
idation and oxidative fragmentation of DNA. The free radicals generated due to gluco-
toxicity can be well scavenged by antioxidant phytochemicals. Interestingly, the ﬁnd-
ings from in silico investigation showed that stevioside has antioxidant and anti NO
property; and these could have accounted for the in vivo eﬀects in the liver and kidney
of the diabetic rats. Although NO is a potent antioxidant, it is often converted to perox-
ynitrite in the presence of ROS and can damage biomolecules in this state [46].
An important ﬁnding of this study is the ability of stevioside to reverse intra-
nucleosomal DNA fragmentation in the liver and kidney rats. This DNA fragmenta-
tion was more prominent in the kidney than the liver. This could be due to the acti-
vation of angiostensin-converting enzyme. Kawahito et al [56] stated that activation
of ACE enhances glucotoxicity-induced apoptosis.on.2018.e00640
ors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Our ﬁndings suggest that the use of stevioside could be beneﬁcial in preventing
oxidative DNA damage observed in T2DM. This is in addition to its antioxidant
and antihyperglycemic properties, particularly in potentially inhibiting glucose ab-
sorption. This also further supports its nutraceutical role as a component of the S.
rebaudiana-derived sugar substitute, especially in T2DM patients.Declarations
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